Pirtobrutinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50mg, 100mg
Reference Brands: Jaypirca(USA/EU)
Category: Oncology Cancer Care
Pirtobrutinib is a highly selective, non-covalent BTK inhibitor designed to overcome resistance to earlier BTK inhibitors. It is used in the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma. By reversibly inhibiting BTK, it blocks signaling required for cancer cell survival and proliferation. Pirtobrutinib is available in Tablets and strengths such as 50mg, 100mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Pirtobrutinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Pirtobrutinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Pirtobrutinib is used for the treatment of relapsed or refractory mantle cell lymphoma (MCL) and certain previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It helps inhibit cancer cell growth by targeting the BTK pathway.
Pirtobrutinib is made from a highly selective, non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor designed to target both wild-type and resistant BTK mutations.
The trade name is Jaypirca.
Jaypirca is manufactured by Eli Lilly and Company.
The generic name is Pirtobrutinib.
The brand name is Jaypirca.
It is manufactured by Eli Lilly in its regulated production facilities in the United States and other global sites for international supply.
Related Products
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
